Cargando…

Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes

This analysis reports a quantitative modeling and simulation approach for oral dapagliflozin, a primarily uridine diphosphate‐glucuronosyltransferase (UGT)–metabolized human sodium‐glucose cotransporter 2 selective inhibitor. A mechanistic dapagliflozin physiologically based pharmacokinetic (PBPK) m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Heeseung, Pilla Reddy, Venkatesh, Parkinson, Joanna, Boulton, David W., Tang, Weifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894404/ https://www.ncbi.nlm.nih.gov/pubmed/33439535 http://dx.doi.org/10.1002/psp4.12577

Ejemplares similares

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
por: Parkinson, Joanna, et al.
Publicado: (2019)

Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
por: Sokolov, Victor, et al.
Publicado: (2018)

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
por: Sokolov, Victor, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus
por: Naagaard, M. Daniel, et al.
Publicado: (2022)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population
por: Lim, Andrew, et al.
Publicado: (2023)

Clinical studies of dapagliflozin in pediatric patients: a rapid review
por: Grube, Paige M., et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
por: Sokolov, Victor, et al.
Publicado: (2023)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin
por: Sertbas, Meltem, et al.
Publicado: (2019)

Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2023)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis
por: Wang, Qianwen, et al.
Publicado: (2022)

Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients
por: Combes, Francois Pierre, et al.
Publicado: (2020)

Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
por: Wilcox, Christopher S., et al.
Publicado: (2018)

Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium
por: van Groen, Bianca D., et al.
Publicado: (2020)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
por: Erdogan, Mumin Alper, et al.
Publicado: (2018)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives
por: Nashar, Khaled, et al.
Publicado: (2022)

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
por: Faraj, Alan, et al.
Publicado: (2023)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report
por: Chou, Yu-Mou, et al.
Publicado: (2018)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

An exploration of the experience of dapagliflozin in clinical practice
por: Anitha, Anuba Paulvarnan, et al.
Publicado: (2022)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
por: Tang, Yi, et al.
Publicado: (2022)

Blood glucose levels and bodyweight change after dapagliflozin administration
por: Kim, Hyunah, et al.
Publicado: (2021)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
por: Aberle, Jens, et al.
Publicado: (2020)

Incorporating human exposure information in a weight of evidence approach to inform design of repeated dose animal studies
por: Lowe, Kelly, et al.
Publicado: (2021)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
por: Shi, Zepeng, et al.
Publicado: (2022)

Insulin dose reduction in dapagliflozin combination therapy for type 1 diabetes mellitus: the RISING-STAR study
por: Hamaguchi, Masahide, et al.
Publicado: (2022)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qm397hssja0i2jouehmjjac92a